Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Sells $1,500,000.00 in Stock
Insider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Sells $1,500,000.00 in Stock
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) insider Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now directly owns 8,397 shares of the company's stock, valued at approximately $251,910. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
BioXcel治疗公司(纳斯达克：BTAI-GET评级)内部人士Frank Yocca在1月20日(星期五)的一笔交易中出售了50,000股BioXcel治疗公司的股票。这只股票的平均售价为30.00美元，总价值为1500,000.00美元。交易完成后，这位内部人士现在直接持有该公司8,397股股票，价值约251,910美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过此超链接.
BioXcel Therapeutics Stock Up 2.8 %
BioXcel治疗公司股票上涨2.8%
Shares of NASDAQ:BTAI opened at $32.01 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 10.28 and a current ratio of 10.34. BioXcel Therapeutics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.96. The stock has a market capitalization of $896.98 million, a P/E ratio of -6.55 and a beta of 1.16. The stock has a 50-day simple moving average of $21.69 and a 200-day simple moving average of $16.43.
纳斯达克：北泰周五开盘报32.01美元。该公司的负债权益比率为0.72，速动比率为10.28，流动比率为10.34。BioXcel治疗公司的一年低点为8.80美元，一年高位为32.96美元。该股市值为8.9698亿美元，市盈率为-6.55，贝塔系数为1.16。该股的50日简单移动均线切入位为21.69美元，200日简单移动均线切入位为16.43美元。
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.15). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.05 million. Equities analysts forecast that BioXcel Therapeutics, Inc. will post -5.37 earnings per share for the current year.
BioXcel治疗公司(纳斯达克代码：BTAI-GET Rating)最近一次发布财报是在11月10日星期四。该公司公布本季度每股收益(EPS)为1.49美元，低于分析师一致预期的1.34美元和0.15美元。该公司本季度营收为14万美元，而分析师预期为305万美元。股票分析师预测，BioXcel治疗公司本年度每股收益将达到5.37美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Hedge Funds Weigh In On BioXcel Therapeutics
对冲基金入股BioXcel治疗公司
A number of institutional investors and hedge funds have recently bought and sold shares of BTAI. Millennium Management LLC boosted its holdings in BioXcel Therapeutics by 872.6% in the 2nd quarter. Millennium Management LLC now owns 188,548 shares of the company's stock worth $2,489,000 after acquiring an additional 169,163 shares during the period. Nuveen Asset Management LLC raised its position in shares of BioXcel Therapeutics by 95.5% in the 3rd quarter. Nuveen Asset Management LLC now owns 217,624 shares of the company's stock valued at $2,572,000 after purchasing an additional 106,314 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioXcel Therapeutics by 330.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 125,280 shares of the company's stock valued at $2,620,000 after purchasing an additional 96,180 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of BioXcel Therapeutics by 569.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 91,039 shares of the company's stock valued at $1,202,000 after purchasing an additional 77,449 shares in the last quarter. Finally, State Street Corp raised its position in shares of BioXcel Therapeutics by 4.1% during the 1st quarter. State Street Corp now owns 1,400,753 shares of the company's stock valued at $29,290,000 after acquiring an additional 55,657 shares in the last quarter. Hedge funds and other institutional investors own 42.35% of the company's stock.
多家机构投资者和对冲基金最近买卖了北泰的股票。千禧管理有限责任公司在第二季度增持了872.6%的BioXcel治疗公司的股份。Millennium Management LLC现在拥有188,548股该公司的股票，价值2,489,000美元，在此期间又购买了169,163股。Nuveen Asset Management LLC在第三季度将其在BioXcel Treateutics的股票头寸提高了95.5%。Nuveen Asset Management LLC在上个季度额外购买了106,314股票后，现在拥有217,624股该公司股票，价值2,572,000美元。Dimension Fund Advisors LP在第一季度将其在BioXcel Treateutics的股票头寸提高了330.5%。Dimension Fund Advisors LP现在拥有125,280股该公司的股票，价值2,620,000美元，上个季度又购买了96,180股。Cubist Systems Strategy LLC在第二季度将其在BioXcel治疗公司的股票持有量提高了569.9%。Cubist Systems Strategy LLC在上个季度又购买了77,449股后，现在拥有91,039股该公司股票，价值1,202,000美元。最后，道富集团在第一季度将其在BioXcel治疗公司的股票头寸提高了4.1%。道富银行目前持有1,400,753股该公司股票，价值29，29万美元，上一季度又收购了55,657股。对冲基金和其他机构投资者持有该公司42.35%的股票。
About BioXcel Therapeutics
关于BioXcel治疗公司
(Get Rating)
(获取评级)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
BioXcel治疗公司是一家商业阶段的生物制药公司，利用人工智能方法开发神经科学和免疫肿瘤学的变革性药物。该公司的药物再创新方法利用现有的批准药物和/或临床验证的候选产品，以及大数据和专有机器学习算法来识别新的治疗指数。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 免费获取StockNews.com关于BioXcel治疗(BTAI)的研究报告
- 石油服务公司NOV有足够的能量维持涨势吗？
- Shopify Clears杯柄基地：势头还能持续吗？
- 雪佛龙以750亿美元的股票回购取悦股东
- 电子商务的未来：分析和新数据
- 列维·施特劳斯非常适合收益型投资者
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受BioXcel治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioXcel治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。